IB10 sphingotest® NT-proBNP
IB10 sphingotest® NT-proBNP is a rapid point-of-care (POC) immunoassay for the quantitative in vitro determination of N-terminal pro-brain natriuretic peptide (NT-proBNP) in human whole blood or plasma using EDTA or Lithium-Heparin as the anticoagulant.
The test is designed for professional use only and may be used on sites where near patient testing is practiced.
Cat. No. IVR-IB56 | NT-proBNP (package of 10 discs)
Clinical Significance
NT-proBNP (1) is a valuable diagnostic and prognostic marker for cardio-vascular diseases, especially in patients with a New York Heart Association (NYHA) Class I-IV Congestive Heart Failure (CHF). (2,3) The measurement of NT-proBNP is an important tool for aiding in the diagnosis and the assessment of the severity of patients with CHF. (4,5)
Expected Values
Recommended Decision Threshold Values:
- Patients under 75 years of age: 125 pg/mL
- Patients 75 years of age and older: 450 pg/mL
Each laboratory should establish a reference range that represents the patient population that is to be evaluated.
Whole Blood vs. Plasma Comparison
All our assays correlate with r=0.9. For more detailed information please read the IFUs or connect with our sales representatives.
Key Features
| Easy Handling | |
|---|---|
| Sample Type | EDTA or Lithium-Heparin Whole Blood or Plasma Samples |
| Time to Result | 20 minutes |
| Measuring Range | 30 - 5,000 pg/mL |
| Limit of Detection | 30 pg/mL |
| No High Dose Hook Effect | up to 300,000 pg/mL |
| Analyte Stability for IB10 Measurement | 24 hours for whole blood |
Request a quote
IB10 sphingotest® NT-proBNP is a rapid point-of-care (POC) immunoassay for the in vitro quantitative determination of N-terminal pro-brain natriuretic peptide.
References
(1) Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail. 2005 Jun;11(5 Suppl):S81-3.
(2) Costello-Boerrigter et al. The prognostic value of N-terminal proB-type natriuretic peptide. Nat Clin Pract Cardiovasc Med. 2005 Apr;2(4):194-201.
(3) Cowie et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003 Oct;24(19):1710-8.
(4) Salah K et al. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart 2019;105:1182-1189.
(5) McDonagh TA et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail. 2004 Mar 15;6(3):269-73.